HSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's

By Reuters News

** HSBC maintains "buy" and raises TP to 1,525 rupees from 1,375 rupees on Dr. Reddy's Laboratories REDY.NS, citing better pricing for semaglutide and stronger growth for India formulations
** Rates "buy" on Apollo Hospitals APLH.NS, Aster DM ATRD.NS, Torrent Pharmaceuticals TORP.NS and Glenmark Pharmaceuticals GLEN.NS, citing stronger earnings visibility

** Brokerage notes that Q2FY27 healthcare earnings were largely in-line, driven by healthy trends in India formulation business and key launches in the U.S.

** Says outlook for health care looks intact despite concerns from trade margin cap on Oncology drugs
** Notes limited impact from higher input and logistics costs due to the Middle East situation; remains watchful

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk